* ongoing or planned therapeutic anticoagulation for any other indication * contra-indication to therapeutic anticoagulation * hypersensitivity to heparin * personal history of heparin-induced thrombocytopenia * suspected or confirmed bacterial endocarditis * bleeding events or tendency due to a suspected or confirmed hemostatic bleeding disorder * organic lesion prone to bleeding * platelet count \<50g/l, hb level \<80g/l * ongoing or recent (\<30 days) major bleeding, ischemic stroke, trauma, surgery * use of dual antiplatelet therapy * pregnancy * bodyweight \<40kg or \>150kg. * end of life care setting * unwillingness to consent * ongoing participation in a covid-19 randomized clinical trial testing another therapeutic intervention

* ongoing or planned therapeutic anticoagulation for any other indication * contra-indication to therapeutic anticoagulation * hypersensitivity to heparin * personal history of heparin-induced thrombocytopenia * suspected or confirmed bacterial endocarditis * bleeding events or tendency due to a suspected or confirmed hemostatic bleeding disorder * organic lesion prone to bleeding * platelet count \<50g/l, hb level \<80g/l * ongoing or recent (\<30 days) major bleeding, ischemic stroke, trauma, surgery * use of dual antiplatelet therapy * pregnancy * bodyweight \<40kg or \>150kg. * end of life care setting * unwillingness to consent * ongoing participation in a covid-19 randomized clinical trial testing another therapeutic intervention

- ongoing or planned therapeutic anticoagulation for any other indication - contra-indication to therapeutic anticoagulation - hypersensitivity to heparin - personal history of heparin-induced thrombocytopenia - suspected or confirmed bacterial endocarditis - bleeding events or tendency due to a suspected or confirmed hemostatic bleeding disorder - organic lesion prone to bleeding - platelet count <50g/l, hb level <80g/l - ongoing or recent (<30 days) major bleeding, ischemic stroke, trauma, surgery - use of dual antiplatelet therapy - pregnancy - bodyweight <40kg or >150kg. - end of life care setting - unwillingness to consent - ongoing participation in a covid-19 randomized clinical trial testing another therapeutic intervention

- ongoing or planned therapeutic anticoagulation for any other indication - contra-indication to therapeutic anticoagulation - hypersensitivity to heparin - personal history of heparin-induced thrombocytopenia - suspected or confirmed bacterial endocarditis - bleeding events or tendency due to a suspected or confirmed hemostatic bleeding disorder - organic lesion prone to bleeding - platelet count <50g/l, hb level <80g/l - ongoing or recent (<30 days) major bleeding, ischemic stroke, trauma, surgery - use of dual antiplatelet therapy - pregnancy - bodyweight <40kg or >150kg. - end of life care setting - unwillingness to consent - ongoing participation in a covid-19 randomized clinical trial testing another therapeutic intervention